Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Apidra

×

Overview

What is Apidra?

APIDRA (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of (K12). Insulin glulisine differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, insulin glulisine is 3-lysine-29-glutamic acid-human insulin, has the empirical formula CHNOSand a molecular weight of 5823 and has the following structural formula:

APIDRA is a sterile, aqueous, clear, and colorless solution. Each milliliter of APIDRA contains 100 units (3.49 mg) insulin glulisine, 3.15 mg metacresol, 6 mg tromethamine, 5 mg sodium chloride, 0.01 mg polysorbate 20, and water for injection. APIDRA has a pH of approximately 7.3. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.



What does Apidra look like?



What are the available doses of Apidra?

APIDRA 100 units/mL (U-100) is available as: ()

What should I talk to my health care provider before I take Apidra?

How should I use Apidra?

APIDRA is indicated to improve glycemic control in adults and children with diabetes mellitus.

APIDRA is a recombinant insulin analog that is equipotent to human insulin (i.e. one unit of APIDRA has the same glucose-lowering effect as one unit of regular human insulin) when given intravenously. When given subcutaneously, APIDRA has a more rapid onset of action and a shorter duration of action than regular human insulin.

The dosage of APIDRA must be individualized. Blood glucose monitoring is essential in all patients receiving insulin therapy.

The total daily insulin requirement may vary and is usually between 0.5 to 1 Unit/kg/day. Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs.


What interacts with Apidra?

Sorry No Records found


What are the warnings of Apidra?

Sorry No Records found


What are the precautions of Apidra?

Sorry No Records found


What are the side effects of Apidra?

Sorry No records found


What should I look out for while using Apidra?

APIDRA is contraindicated:


What might happen if I take too much Apidra?

Excess insulin may cause hypoglycemia and, particularly when given intravenously, hypokalemia. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.


How should I store and handle Apidra?

How SuppliedPantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with “40” on one side and plain on the other side and are available as follows:NDC 42043-371-90, bottles of 90NDC 42043-371-01, bottles of 100Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with “20” on one side and plain on the other side and are available as follows:NDC 42043-370-90, bottles of 90How SuppliedPantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with “40” on one side and plain on the other side and are available as follows:NDC 42043-371-90, bottles of 90NDC 42043-371-01, bottles of 100Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with “20” on one side and plain on the other side and are available as follows:NDC 42043-370-90, bottles of 90How SuppliedPantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with “40” on one side and plain on the other side and are available as follows:NDC 42043-371-90, bottles of 90NDC 42043-371-01, bottles of 100Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with “20” on one side and plain on the other side and are available as follows:NDC 42043-370-90, bottles of 90How SuppliedPantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with “40” on one side and plain on the other side and are available as follows:NDC 42043-371-90, bottles of 90NDC 42043-371-01, bottles of 100Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with “20” on one side and plain on the other side and are available as follows:NDC 42043-370-90, bottles of 90How SuppliedPantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, oval shaped, enteric coated tablets imprinted with “40” on one side and plain on the other side and are available as follows:NDC 42043-371-90, bottles of 90NDC 42043-371-01, bottles of 100Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, oval shaped, enteric coated tablets imprinted with “20” on one side and plain on the other side and are available as follows:NDC 42043-370-90, bottles of 90